393 related articles for article (PubMed ID: 16721128)
1. Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior.
McArthur GA
Curr Opin Oncol; 2006 Jul; 18(4):341-6. PubMed ID: 16721128
[TBL] [Abstract][Full Text] [Related]
2. [New molecular approaches in dermatofibrosarcoma protuberans].
Kaya G
Rev Med Suisse; 2009 Jul; 5(211):1519-24. PubMed ID: 19694363
[TBL] [Abstract][Full Text] [Related]
3. Dermatofibrosarcoma protuberans: recent clinical progress.
McArthur G
Ann Surg Oncol; 2007 Oct; 14(10):2876-86. PubMed ID: 17647063
[TBL] [Abstract][Full Text] [Related]
4. [Molecular approach in the treatment of dermatofibrosarcoma protuberans].
Fattoruso SI; Visca P; Lopez M
Clin Ter; 2008; 159(5):361-7. PubMed ID: 18998038
[TBL] [Abstract][Full Text] [Related]
5. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
McArthur GA; Demetri GD; van Oosterom A; Heinrich MC; Debiec-Rychter M; Corless CL; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2005 Feb; 23(4):866-73. PubMed ID: 15681532
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.
Rutkowski P; Dębiec-Rychter M; Nowecki Z; Michej W; Symonides M; Ptaszynski K; Ruka W
J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):264-70. PubMed ID: 20569296
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.
Kérob D; Porcher R; Vérola O; Dalle S; Maubec E; Aubin F; D'Incan M; Bodokh I; Boulinguez S; Madelaine-Chambrin I; Mathieu-Boue A; Servant JM; de Kerviler E; Janin A; Calvo F; Pedeutour F; Lebbe C
Clin Cancer Res; 2010 Jun; 16(12):3288-95. PubMed ID: 20439456
[TBL] [Abstract][Full Text] [Related]
9. [From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors].
Bianchini L; Maire G; Pedeutour F;
Bull Cancer; 2007 Feb; 94(2):179-89. PubMed ID: 17337387
[TBL] [Abstract][Full Text] [Related]
10. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management.
Llombart B; Serra-Guillén C; Monteagudo C; López Guerrero JA; Sanmartín O
Semin Diagn Pathol; 2013 Feb; 30(1):13-28. PubMed ID: 23327727
[TBL] [Abstract][Full Text] [Related]
11. Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate.
Fiore M; Miceli R; Mussi C; Lo Vullo S; Mariani L; Lozza L; Collini P; Olmi P; Casali PG; Gronchi A
J Clin Oncol; 2005 Oct; 23(30):7669-75. PubMed ID: 16234529
[TBL] [Abstract][Full Text] [Related]
12. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications.
Llombart B; Sanmartín O; López-Guerrero JA; Monteagudo C; Serra C; Requena C; Poveda A; Vistós JL; Almenar S; Llombart-Bosch A; Guillén C
Histopathology; 2009 Jun; 54(7):860-72. PubMed ID: 19635106
[TBL] [Abstract][Full Text] [Related]
13. Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease.
McArthur GA
J Natl Compr Canc Netw; 2007 May; 5(5):557-62. PubMed ID: 17509258
[TBL] [Abstract][Full Text] [Related]
14. Dermatofibrosarcoma protuberans of the vulva: a clinicopathologic and immunohistochemical study of 13 cases.
Edelweiss M; Malpica A
Am J Surg Pathol; 2010 Mar; 34(3):393-400. PubMed ID: 20139758
[TBL] [Abstract][Full Text] [Related]
15. [Realization of clinical diagnoses and treatment for dermatofibrosarcoma protuberans].
Cai H; Shi YQ; Wang YN; Zhu HY; Mo SJ
Zhonghua Wai Ke Za Zhi; 2004 Jun; 42(11):678-82. PubMed ID: 15329259
[TBL] [Abstract][Full Text] [Related]
16. Dermatofibrosarcoma protruberans treatment with platelet-derived growth factor receptor inhibitor: a review of clinical trial results.
Malhotra B; Schuetze SM
Curr Opin Oncol; 2012 Jul; 24(4):419-24. PubMed ID: 22510939
[TBL] [Abstract][Full Text] [Related]
17. A novel fusion gene of collagen type I alpha 1 (exon 31) and platelet-derived growth factor B-chain (exon 2) in dermatofibrosarcoma protuberans.
Nakanishi G; Lin SN; Asagoe K; Suzuki N; Matsuo A; Tanaka R; Makino E; Fujimoto W; Iwatsuki K
Eur J Dermatol; 2007; 17(3):217-9. PubMed ID: 17478383
[TBL] [Abstract][Full Text] [Related]
18. [Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans].
Baars A; Pinedo HM
Ned Tijdschr Geneeskd; 2003 Oct; 147(42):2072-6. PubMed ID: 14606355
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.
Han A; Chen EH; Niedt G; Sherman W; Ratner D
Arch Dermatol; 2009 Jul; 145(7):792-6. PubMed ID: 19620561
[TBL] [Abstract][Full Text] [Related]
20. [Long-term experience with multidisciplinary therapy of twenty-six patients with dermatofibrosarcoma protuberans].
Mátrai Z; Liszkay G; Plotár V; Orosz Z; Székely J; Hitre E; Bartal A; Langmár Z; Bocs K; Rényi Vámos F; Sávolt A; Tóth L
Orv Hetil; 2009 Oct; 150(41):1894-902. PubMed ID: 19801356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]